Enanta Pharmaceueticals Inc., of Watertown, Mass., said partner Abbvie Inc., of Chicago, submitted a marketing authorization application for ABT-450 to the EMA seeking approval of the all-oral, interferon-free regimen for the treatment of adults infected with chronic genotype 1 hepatitis C virus.